nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A1—prostate cancer	0.186	0.503	CbGaD
Epinephrine—ADRB2—prostate cancer	0.119	0.321	CbGaD
Epinephrine—CYP3A4—prostate cancer	0.065	0.176	CbGaD
Epinephrine—SLC22A2—Estradiol—prostate cancer	0.029	0.0913	CbGbCtD
Epinephrine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0256	0.0805	CbGbCtD
Epinephrine—SLC22A1—Estradiol—prostate cancer	0.0252	0.0793	CbGbCtD
Epinephrine—CYP2C9—Nilutamide—prostate cancer	0.0232	0.0727	CbGbCtD
Epinephrine—CYP2C9—Bicalutamide—prostate cancer	0.0232	0.0727	CbGbCtD
Epinephrine—CYP1A2—Flutamide—prostate cancer	0.0213	0.0669	CbGbCtD
Epinephrine—ADRA1B—vas deferens—prostate cancer	0.0155	0.309	CbGeAlD
Epinephrine—CYP1A2—Estrone—prostate cancer	0.0154	0.0484	CbGbCtD
Epinephrine—CYP2C9—Estrone—prostate cancer	0.0139	0.0436	CbGbCtD
Epinephrine—CYP3A4—Bicalutamide—prostate cancer	0.0135	0.0423	CbGbCtD
Epinephrine—CYP3A4—Estramustine—prostate cancer	0.0125	0.0393	CbGbCtD
Epinephrine—CYP3A4—Abiraterone—prostate cancer	0.0112	0.035	CbGbCtD
Epinephrine—CYP3A4—Flutamide—prostate cancer	0.0112	0.035	CbGbCtD
Epinephrine—CYP2C9—Capecitabine—prostate cancer	0.0105	0.033	CbGbCtD
Epinephrine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0101	0.0316	CbGbCtD
Epinephrine—CYP1A2—Estradiol—prostate cancer	0.00884	0.0278	CbGbCtD
Epinephrine—CYP3A4—Cabazitaxel—prostate cancer	0.00825	0.0259	CbGbCtD
Epinephrine—CYP3A4—Estrone—prostate cancer	0.00807	0.0253	CbGbCtD
Epinephrine—CYP2C9—Estradiol—prostate cancer	0.00797	0.025	CbGbCtD
Epinephrine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00719	0.0226	CbGbCtD
Epinephrine—CYP1A2—Etoposide—prostate cancer	0.00577	0.0181	CbGbCtD
Epinephrine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00528	0.0166	CbGbCtD
Epinephrine—CYP3A4—Mitoxantrone—prostate cancer	0.0048	0.0151	CbGbCtD
Epinephrine—CYP3A4—Estradiol—prostate cancer	0.00463	0.0146	CbGbCtD
Epinephrine—CYP3A4—Prednisone—prostate cancer	0.00398	0.0125	CbGbCtD
Epinephrine—CYP3A4—Etoposide—prostate cancer	0.00302	0.0095	CbGbCtD
Epinephrine—CYP3A4—Docetaxel—prostate cancer	0.00277	0.00869	CbGbCtD
Epinephrine—ADRB3—prostate gland—prostate cancer	0.0024	0.0479	CbGeAlD
Epinephrine—ADRBK1—prostate gland—prostate cancer	0.00235	0.0468	CbGeAlD
Epinephrine—PAH—renal system—prostate cancer	0.0021	0.0418	CbGeAlD
Epinephrine—CYP3A4—Doxorubicin—prostate cancer	0.00206	0.00648	CbGbCtD
Epinephrine—CYP1A2—urine—prostate cancer	0.00179	0.0357	CbGeAlD
Epinephrine—CYP2C9—urine—prostate cancer	0.0017	0.0339	CbGeAlD
Epinephrine—ADRBK1—renal system—prostate cancer	0.0016	0.0319	CbGeAlD
Epinephrine—ADRA1D—prostate gland—prostate cancer	0.00135	0.027	CbGeAlD
Epinephrine—TNF—lymph node—prostate cancer	0.00131	0.026	CbGeAlD
Epinephrine—CYP3A4—urine—prostate cancer	0.0013	0.0258	CbGeAlD
Epinephrine—ADRBK1—bone marrow—prostate cancer	0.00121	0.0241	CbGeAlD
Epinephrine—ADRBK1—testis—prostate cancer	0.00103	0.0206	CbGeAlD
Epinephrine—ADRA1D—epithelium—prostate cancer	0.000994	0.0198	CbGeAlD
Epinephrine—SLC22A2—renal system—prostate cancer	0.000985	0.0196	CbGeAlD
Epinephrine—ADRB1—prostate gland—prostate cancer	0.000983	0.0196	CbGeAlD
Epinephrine—ADRA1B—renal system—prostate cancer	0.000943	0.0188	CbGeAlD
Epinephrine—ADRA1D—urethra—prostate cancer	0.000906	0.018	CbGeAlD
Epinephrine—ADRA1A—prostate gland—prostate cancer	0.000777	0.0155	CbGeAlD
Epinephrine—ADRBK1—lymph node—prostate cancer	0.00075	0.0149	CbGeAlD
Epinephrine—ADRA2C—prostate gland—prostate cancer	0.00074	0.0148	CbGeAlD
Epinephrine—SLC22A5—prostate gland—prostate cancer	0.000709	0.0141	CbGeAlD
Epinephrine—SLC22A1—renal system—prostate cancer	0.000696	0.0139	CbGeAlD
Epinephrine—ADRA2C—seminal vesicle—prostate cancer	0.000626	0.0125	CbGeAlD
Epinephrine—SLC22A5—seminal vesicle—prostate cancer	0.0006	0.012	CbGeAlD
Epinephrine—ADRA2A—prostate gland—prostate cancer	0.000591	0.0118	CbGeAlD
Epinephrine—Dipivefrin—ACHE—prostate cancer	0.000576	0.138	CrCbGaD
Epinephrine—ADRA1A—epithelium—prostate cancer	0.000571	0.0114	CbGeAlD
Epinephrine—ADRA1A—renal system—prostate cancer	0.00053	0.0106	CbGeAlD
Epinephrine—ADRA2C—renal system—prostate cancer	0.000505	0.0101	CbGeAlD
Epinephrine—ADRA2A—seminal vesicle—prostate cancer	0.0005	0.00996	CbGeAlD
Epinephrine—ADRA2C—urethra—prostate cancer	0.000496	0.00988	CbGeAlD
Epinephrine—SLC22A5—renal system—prostate cancer	0.000483	0.00963	CbGeAlD
Epinephrine—SLC22A5—urethra—prostate cancer	0.000475	0.00946	CbGeAlD
Epinephrine—CYP1A2—renal system—prostate cancer	0.000438	0.00873	CbGeAlD
Epinephrine—ADRA2A—urethra—prostate cancer	0.000396	0.00788	CbGeAlD
Epinephrine—Orciprenaline—ADRB2—prostate cancer	0.000384	0.0919	CrCbGaD
Epinephrine—Methyldopa—COMT—prostate cancer	0.000332	0.0795	CrCbGaD
Epinephrine—ADRA2C—testis—prostate cancer	0.000326	0.0065	CbGeAlD
Epinephrine—CYP3A4—renal system—prostate cancer	0.000317	0.00632	CbGeAlD
Epinephrine—SLC22A5—testis—prostate cancer	0.000312	0.00623	CbGeAlD
Epinephrine—Pirbuterol—ADRB2—prostate cancer	0.00031	0.0741	CrCbGaD
Epinephrine—Dipivefrin—ADRB2—prostate cancer	0.000291	0.0697	CrCbGaD
Epinephrine—ADRA2A—testis—prostate cancer	0.00026	0.00519	CbGeAlD
Epinephrine—Terbutaline—ADRB2—prostate cancer	0.000253	0.0604	CrCbGaD
Epinephrine—Isoetarine—ADRB2—prostate cancer	0.000243	0.0582	CrCbGaD
Epinephrine—ADRA2C—lymph node—prostate cancer	0.000236	0.00471	CbGeAlD
Epinephrine—SLC22A5—lymph node—prostate cancer	0.000226	0.00451	CbGeAlD
Epinephrine—Norepinephrine—SLC22A3—prostate cancer	0.000204	0.0489	CrCbGaD
Epinephrine—Arbutamine—ADRB2—prostate cancer	0.000193	0.0462	CrCbGaD
Epinephrine—Dopamine—SLC22A3—prostate cancer	0.00019	0.0454	CrCbGaD
Epinephrine—ADRA2A—lymph node—prostate cancer	0.000189	0.00376	CbGeAlD
Epinephrine—Salbutamol—ADRB2—prostate cancer	0.000188	0.0449	CrCbGaD
Epinephrine—Haemoglobin—Estradiol—prostate cancer	0.000187	0.00153	CcSEcCtD
Epinephrine—Haemorrhage—Estradiol—prostate cancer	0.000186	0.00152	CcSEcCtD
Epinephrine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000185	0.00151	CcSEcCtD
Epinephrine—Sweating—Mitoxantrone—prostate cancer	0.000185	0.00151	CcSEcCtD
Epinephrine—Hypoaesthesia—Estradiol—prostate cancer	0.000185	0.00151	CcSEcCtD
Epinephrine—Dizziness—Cabazitaxel—prostate cancer	0.000184	0.00151	CcSEcCtD
Epinephrine—Extravasation—Epirubicin—prostate cancer	0.000184	0.00151	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisone—prostate cancer	0.000183	0.0015	CcSEcCtD
Epinephrine—Renal impairment—Docetaxel—prostate cancer	0.000182	0.00149	CcSEcCtD
Epinephrine—Palpitations—Goserelin—prostate cancer	0.00018	0.00147	CcSEcCtD
Epinephrine—Palpitations—Conjugated Estrogens—prostate cancer	0.000178	0.00146	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Epirubicin—prostate cancer	0.000178	0.00146	CcSEcCtD
Epinephrine—Vomiting—Cabazitaxel—prostate cancer	0.000177	0.00145	CcSEcCtD
Epinephrine—Hypertension—Goserelin—prostate cancer	0.000176	0.00144	CcSEcCtD
Epinephrine—Renal impairment—Capecitabine—prostate cancer	0.000176	0.00144	CcSEcCtD
Epinephrine—Nausea—Degarelix—prostate cancer	0.000176	0.00144	CcSEcCtD
Epinephrine—Sweating increased—Etoposide—prostate cancer	0.000175	0.00143	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000175	0.00143	CcSEcCtD
Epinephrine—Haemoglobin—Mitoxantrone—prostate cancer	0.000174	0.00142	CcSEcCtD
Epinephrine—Chest pain—Goserelin—prostate cancer	0.000174	0.00142	CcSEcCtD
Epinephrine—Haemorrhage—Mitoxantrone—prostate cancer	0.000173	0.00142	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000172	0.00141	CcSEcCtD
Epinephrine—Flushing—Estradiol—prostate cancer	0.000172	0.00141	CcSEcCtD
Epinephrine—Chest pain—Conjugated Estrogens—prostate cancer	0.000172	0.00141	CcSEcCtD
Epinephrine—Cerebrovascular accident—Capecitabine—prostate cancer	0.000171	0.0014	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000171	0.0014	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—prostate cancer	0.00017	0.00139	CcSEcCtD
Epinephrine—Nausea—Cabazitaxel—prostate cancer	0.000166	0.00136	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Doxorubicin—prostate cancer	0.000165	0.00135	CcSEcCtD
Epinephrine—Nervous system disorder—Goserelin—prostate cancer	0.000163	0.00134	CcSEcCtD
Epinephrine—Mental disorder—Estradiol—prostate cancer	0.000163	0.00133	CcSEcCtD
Epinephrine—Tachycardia—Goserelin—prostate cancer	0.000162	0.00133	CcSEcCtD
Epinephrine—Dopamine—COMT—prostate cancer	0.000162	0.0388	CrCbGaD
Epinephrine—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000162	0.00132	CcSEcCtD
Epinephrine—Erythema—Estradiol—prostate cancer	0.000162	0.00132	CcSEcCtD
Epinephrine—Skin disorder—Goserelin—prostate cancer	0.000162	0.00132	CcSEcCtD
Epinephrine—Hyperhidrosis—Goserelin—prostate cancer	0.000161	0.00132	CcSEcCtD
Epinephrine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000161	0.00132	CcSEcCtD
Epinephrine—Skin disorder—Conjugated Estrogens—prostate cancer	0.00016	0.00131	CcSEcCtD
Epinephrine—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000159	0.0013	CcSEcCtD
Epinephrine—Tension—Estradiol—prostate cancer	0.000159	0.0013	CcSEcCtD
Epinephrine—Dizziness—Bicalutamide—prostate cancer	0.000158	0.00129	CcSEcCtD
Epinephrine—Acute coronary syndrome—Etoposide—prostate cancer	0.000158	0.00129	CcSEcCtD
Epinephrine—Renal failure—Etoposide—prostate cancer	0.000158	0.00129	CcSEcCtD
Epinephrine—Myocardial infarction—Etoposide—prostate cancer	0.000157	0.00129	CcSEcCtD
Epinephrine—Nervousness—Estradiol—prostate cancer	0.000157	0.00128	CcSEcCtD
Epinephrine—Arrhythmia—Mitoxantrone—prostate cancer	0.000155	0.00126	CcSEcCtD
Epinephrine—Skin exfoliation—Epirubicin—prostate cancer	0.000153	0.00126	CcSEcCtD
Epinephrine—Hypokalaemia—Capecitabine—prostate cancer	0.000152	0.00125	CcSEcCtD
Epinephrine—Vomiting—Bicalutamide—prostate cancer	0.000152	0.00124	CcSEcCtD
Epinephrine—Erythema—Mitoxantrone—prostate cancer	0.000151	0.00123	CcSEcCtD
Epinephrine—Insomnia—Goserelin—prostate cancer	0.00015	0.00123	CcSEcCtD
Epinephrine—Paraesthesia—Goserelin—prostate cancer	0.000149	0.00122	CcSEcCtD
Epinephrine—Insomnia—Conjugated Estrogens—prostate cancer	0.000149	0.00122	CcSEcCtD
Epinephrine—Agitation—Estradiol—prostate cancer	0.000149	0.00122	CcSEcCtD
Epinephrine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000148	0.00121	CcSEcCtD
Epinephrine—Somnolence—Goserelin—prostate cancer	0.000148	0.00121	CcSEcCtD
Epinephrine—Norepinephrine—SLC22A1—prostate cancer	0.000147	0.035	CrCbGaD
Epinephrine—Somnolence—Conjugated Estrogens—prostate cancer	0.000147	0.0012	CcSEcCtD
Epinephrine—Psychotic disorder—Prednisone—prostate cancer	0.000146	0.00119	CcSEcCtD
Epinephrine—Hypoaesthesia—Etoposide—prostate cancer	0.000143	0.00117	CcSEcCtD
Epinephrine—Pulmonary oedema—Epirubicin—prostate cancer	0.000143	0.00117	CcSEcCtD
Epinephrine—Palpitations—Estradiol—prostate cancer	0.000143	0.00117	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000142	0.00116	CcSEcCtD
Epinephrine—Nausea—Bicalutamide—prostate cancer	0.000142	0.00116	CcSEcCtD
Epinephrine—Skin exfoliation—Doxorubicin—prostate cancer	0.000142	0.00116	CcSEcCtD
Epinephrine—Sweating increased—Capecitabine—prostate cancer	0.000141	0.00115	CcSEcCtD
Epinephrine—Hypertension—Estradiol—prostate cancer	0.00014	0.00114	CcSEcCtD
Epinephrine—Chest pain—Estradiol—prostate cancer	0.000138	0.00113	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000137	0.00112	CcSEcCtD
Epinephrine—Dopamine—SLC22A1—prostate cancer	0.000136	0.0326	CrCbGaD
Epinephrine—Hypokalaemia—Prednisone—prostate cancer	0.000136	0.00111	CcSEcCtD
Epinephrine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000134	0.00109	CcSEcCtD
Epinephrine—Flushing—Etoposide—prostate cancer	0.000134	0.00109	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—prostate cancer	0.000132	0.00108	CcSEcCtD
Epinephrine—Acute coronary syndrome—Docetaxel—prostate cancer	0.000131	0.00107	CcSEcCtD
Epinephrine—Renal failure—Docetaxel—prostate cancer	0.000131	0.00107	CcSEcCtD
Epinephrine—Myocardial infarction—Docetaxel—prostate cancer	0.000131	0.00107	CcSEcCtD
Epinephrine—Hyperglycaemia—Capecitabine—prostate cancer	0.00013	0.00107	CcSEcCtD
Epinephrine—Hypertension—Mitoxantrone—prostate cancer	0.00013	0.00106	CcSEcCtD
Epinephrine—Nervous system disorder—Estradiol—prostate cancer	0.000129	0.00106	CcSEcCtD
Epinephrine—Tachycardia—Estradiol—prostate cancer	0.000129	0.00105	CcSEcCtD
Epinephrine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000129	0.00105	CcSEcCtD
Epinephrine—Chest pain—Mitoxantrone—prostate cancer	0.000128	0.00105	CcSEcCtD
Epinephrine—Skin disorder—Estradiol—prostate cancer	0.000128	0.00105	CcSEcCtD
Epinephrine—Hyperhidrosis—Estradiol—prostate cancer	0.000128	0.00104	CcSEcCtD
Epinephrine—Acute coronary syndrome—Capecitabine—prostate cancer	0.000127	0.00104	CcSEcCtD
Epinephrine—Renal failure—Capecitabine—prostate cancer	0.000127	0.00104	CcSEcCtD
Epinephrine—Myocardial infarction—Capecitabine—prostate cancer	0.000126	0.00103	CcSEcCtD
Epinephrine—Sweating increased—Prednisone—prostate cancer	0.000126	0.00103	CcSEcCtD
Epinephrine—Renal impairment—Epirubicin—prostate cancer	0.000123	0.001	CcSEcCtD
Epinephrine—Haemoglobin—Docetaxel—prostate cancer	0.00012	0.000984	CcSEcCtD
Epinephrine—Nausea—Ethinyl Estradiol—prostate cancer	0.00012	0.000983	CcSEcCtD
Epinephrine—Tachycardia—Mitoxantrone—prostate cancer	0.00012	0.000982	CcSEcCtD
Epinephrine—Haemorrhage—Docetaxel—prostate cancer	0.00012	0.000979	CcSEcCtD
Epinephrine—Hypoglycaemia—Epirubicin—prostate cancer	0.000119	0.000978	CcSEcCtD
Epinephrine—Skin disorder—Mitoxantrone—prostate cancer	0.000119	0.000977	CcSEcCtD
Epinephrine—Insomnia—Estradiol—prostate cancer	0.000119	0.000977	CcSEcCtD
Epinephrine—Hypoaesthesia—Docetaxel—prostate cancer	0.000119	0.000974	CcSEcCtD
Epinephrine—Cerebrovascular accident—Epirubicin—prostate cancer	0.000119	0.000974	CcSEcCtD
Epinephrine—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000119	0.000973	CcSEcCtD
Epinephrine—Paraesthesia—Estradiol—prostate cancer	0.000118	0.000969	CcSEcCtD
Epinephrine—Somnolence—Estradiol—prostate cancer	0.000117	0.00096	CcSEcCtD
Epinephrine—Haemoglobin—Capecitabine—prostate cancer	0.000116	0.000952	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—prostate cancer	0.000116	0.000951	CcSEcCtD
Epinephrine—Haemorrhage—Capecitabine—prostate cancer	0.000116	0.000948	CcSEcCtD
Epinephrine—Hypoaesthesia—Capecitabine—prostate cancer	0.000115	0.000943	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Estradiol—prostate cancer	0.000114	0.000932	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—prostate cancer	0.000113	0.000928	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—prostate cancer	0.000113	0.000927	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—prostate cancer	0.000113	0.000922	CcSEcCtD
Epinephrine—Droxidopa—ADRB2—prostate cancer	0.000111	0.0266	CrCbGaD
Epinephrine—Flushing—Docetaxel—prostate cancer	0.000111	0.000908	CcSEcCtD
Epinephrine—Hypoglycaemia—Doxorubicin—prostate cancer	0.000111	0.000905	CcSEcCtD
Epinephrine—Paraesthesia—Mitoxantrone—prostate cancer	0.00011	0.000903	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—prostate cancer	0.00011	0.000901	CcSEcCtD
Epinephrine—Dizziness—Goserelin—prostate cancer	0.00011	0.000901	CcSEcCtD
Epinephrine—Somnolence—Mitoxantrone—prostate cancer	0.000109	0.000894	CcSEcCtD
Epinephrine—Dizziness—Conjugated Estrogens—prostate cancer	0.000109	0.000892	CcSEcCtD
Epinephrine—Hypertension—Etoposide—prostate cancer	0.000108	0.000885	CcSEcCtD
Epinephrine—Flushing—Capecitabine—prostate cancer	0.000107	0.00088	CcSEcCtD
Epinephrine—Arrhythmia—Docetaxel—prostate cancer	0.000107	0.000874	CcSEcCtD
Epinephrine—Chest pain—Etoposide—prostate cancer	0.000107	0.000873	CcSEcCtD
Epinephrine—Hypokalaemia—Epirubicin—prostate cancer	0.000106	0.000869	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000106	0.000867	CcSEcCtD
Epinephrine—Vomiting—Goserelin—prostate cancer	0.000106	0.000866	CcSEcCtD
Epinephrine—Vomiting—Conjugated Estrogens—prostate cancer	0.000105	0.000858	CcSEcCtD
Epinephrine—Mental disorder—Docetaxel—prostate cancer	0.000105	0.000858	CcSEcCtD
Epinephrine—Erythema—Docetaxel—prostate cancer	0.000104	0.000852	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—prostate cancer	0.000104	0.000848	CcSEcCtD
Epinephrine—Arrhythmia—Capecitabine—prostate cancer	0.000103	0.000847	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—prostate cancer	0.000103	0.000844	CcSEcCtD
Epinephrine—Salbutamol—CYP3A4—prostate cancer	0.000103	0.0246	CrCbGaD
Epinephrine—Hallucination—Prednisone—prostate cancer	0.000103	0.00084	CcSEcCtD
Epinephrine—Mental disorder—Capecitabine—prostate cancer	0.000101	0.00083	CcSEcCtD
Epinephrine—Isoprenaline—ADRB2—prostate cancer	0.000101	0.0241	CrCbGaD
Epinephrine—Erythema—Capecitabine—prostate cancer	0.000101	0.000825	CcSEcCtD
Epinephrine—Tachycardia—Etoposide—prostate cancer	9.98e-05	0.000817	CcSEcCtD
Epinephrine—Skin disorder—Etoposide—prostate cancer	9.93e-05	0.000813	CcSEcCtD
Epinephrine—Nausea—Goserelin—prostate cancer	9.88e-05	0.000809	CcSEcCtD
Epinephrine—Hyperhidrosis—Etoposide—prostate cancer	9.88e-05	0.000809	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—prostate cancer	9.82e-05	0.000804	CcSEcCtD
Epinephrine—Nausea—Conjugated Estrogens—prostate cancer	9.79e-05	0.000801	CcSEcCtD
Epinephrine—Flushing—Prednisone—prostate cancer	9.57e-05	0.000783	CcSEcCtD
Epinephrine—Norepinephrine—ADRB2—prostate cancer	9.35e-05	0.0224	CrCbGaD
Epinephrine—Arrhythmia—Prednisone—prostate cancer	9.21e-05	0.000754	CcSEcCtD
Epinephrine—Palpitations—Docetaxel—prostate cancer	9.2e-05	0.000753	CcSEcCtD
Epinephrine—Paraesthesia—Etoposide—prostate cancer	9.18e-05	0.000751	CcSEcCtD
Epinephrine—Hyperglycaemia—Epirubicin—prostate cancer	9.09e-05	0.000744	CcSEcCtD
Epinephrine—Somnolence—Etoposide—prostate cancer	9.09e-05	0.000744	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—prostate cancer	9.04e-05	0.00074	CcSEcCtD
Epinephrine—Hypertension—Docetaxel—prostate cancer	8.99e-05	0.000736	CcSEcCtD
Epinephrine—Drowsiness—Epirubicin—prostate cancer	8.99e-05	0.000735	CcSEcCtD
Epinephrine—Erythema—Prednisone—prostate cancer	8.98e-05	0.000735	CcSEcCtD
Epinephrine—Palpitations—Capecitabine—prostate cancer	8.91e-05	0.000729	CcSEcCtD
Epinephrine—Chest pain—Docetaxel—prostate cancer	8.86e-05	0.000725	CcSEcCtD
Epinephrine—Renal failure—Epirubicin—prostate cancer	8.83e-05	0.000723	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Etoposide—prostate cancer	8.83e-05	0.000722	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.8e-05	0.00072	CcSEcCtD
Epinephrine—Dizziness—Estradiol—prostate cancer	8.72e-05	0.000714	CcSEcCtD
Epinephrine—Hypertension—Capecitabine—prostate cancer	8.7e-05	0.000712	CcSEcCtD
Epinephrine—Isoprenaline—CYP1A1—prostate cancer	8.66e-05	0.0207	CrCbGaD
Epinephrine—Sweating—Epirubicin—prostate cancer	8.61e-05	0.000705	CcSEcCtD
Epinephrine—Chest pain—Capecitabine—prostate cancer	8.58e-05	0.000702	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.52e-05	0.000698	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—prostate cancer	8.41e-05	0.000688	CcSEcCtD
Epinephrine—Vomiting—Estradiol—prostate cancer	8.39e-05	0.000686	CcSEcCtD
Epinephrine—Nervous system disorder—Docetaxel—prostate cancer	8.33e-05	0.000682	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—prostate cancer	8.31e-05	0.00068	CcSEcCtD
Epinephrine—Tachycardia—Docetaxel—prostate cancer	8.29e-05	0.000679	CcSEcCtD
Epinephrine—Skin disorder—Docetaxel—prostate cancer	8.25e-05	0.000675	CcSEcCtD
Epinephrine—Agitation—Prednisone—prostate cancer	8.25e-05	0.000675	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—prostate cancer	8.17e-05	0.000669	CcSEcCtD
Epinephrine—Haemoglobin—Epirubicin—prostate cancer	8.11e-05	0.000664	CcSEcCtD
Epinephrine—Nervous system disorder—Capecitabine—prostate cancer	8.07e-05	0.00066	CcSEcCtD
Epinephrine—Haemorrhage—Epirubicin—prostate cancer	8.07e-05	0.00066	CcSEcCtD
Epinephrine—Tachycardia—Capecitabine—prostate cancer	8.03e-05	0.000657	CcSEcCtD
Epinephrine—Hypoaesthesia—Epirubicin—prostate cancer	8.03e-05	0.000657	CcSEcCtD
Epinephrine—Skin disorder—Capecitabine—prostate cancer	7.99e-05	0.000654	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—prostate cancer	7.97e-05	0.000652	CcSEcCtD
Epinephrine—Hyperhidrosis—Capecitabine—prostate cancer	7.95e-05	0.000651	CcSEcCtD
Epinephrine—Nausea—Estradiol—prostate cancer	7.83e-05	0.000641	CcSEcCtD
Epinephrine—Vomiting—Mitoxantrone—prostate cancer	7.81e-05	0.00064	CcSEcCtD
Epinephrine—Hypertension—Prednisone—prostate cancer	7.75e-05	0.000634	CcSEcCtD
Epinephrine—Insomnia—Docetaxel—prostate cancer	7.68e-05	0.000629	CcSEcCtD
Epinephrine—Paraesthesia—Docetaxel—prostate cancer	7.63e-05	0.000624	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.59e-05	0.000621	CcSEcCtD
Epinephrine—Somnolence—Docetaxel—prostate cancer	7.55e-05	0.000618	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—prostate cancer	7.5e-05	0.000614	CcSEcCtD
Epinephrine—Flushing—Epirubicin—prostate cancer	7.49e-05	0.000613	CcSEcCtD
Epinephrine—Dopamine—CYP2C19—prostate cancer	7.48e-05	0.0179	CrCbGaD
Epinephrine—Haemorrhage—Doxorubicin—prostate cancer	7.46e-05	0.000611	CcSEcCtD
Epinephrine—Insomnia—Capecitabine—prostate cancer	7.44e-05	0.000609	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—prostate cancer	7.43e-05	0.000608	CcSEcCtD
Epinephrine—Paraesthesia—Capecitabine—prostate cancer	7.39e-05	0.000605	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Docetaxel—prostate cancer	7.33e-05	0.0006	CcSEcCtD
Epinephrine—Nausea—Mitoxantrone—prostate cancer	7.3e-05	0.000598	CcSEcCtD
Epinephrine—Arrhythmia—Epirubicin—prostate cancer	7.21e-05	0.00059	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—prostate cancer	7.19e-05	0.000588	CcSEcCtD
Epinephrine—Tachycardia—Prednisone—prostate cancer	7.15e-05	0.000585	CcSEcCtD
Epinephrine—Skin disorder—Prednisone—prostate cancer	7.12e-05	0.000583	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Capecitabine—prostate cancer	7.1e-05	0.000581	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisone—prostate cancer	7.08e-05	0.00058	CcSEcCtD
Epinephrine—Mental disorder—Epirubicin—prostate cancer	7.07e-05	0.000578	CcSEcCtD
Epinephrine—Erythema—Epirubicin—prostate cancer	7.02e-05	0.000575	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—prostate cancer	6.93e-05	0.000567	CcSEcCtD
Epinephrine—Tension—Epirubicin—prostate cancer	6.89e-05	0.000564	CcSEcCtD
Epinephrine—Nervousness—Epirubicin—prostate cancer	6.82e-05	0.000558	CcSEcCtD
Epinephrine—Dizziness—Etoposide—prostate cancer	6.76e-05	0.000553	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—prostate cancer	6.67e-05	0.000546	CcSEcCtD
Epinephrine—Insomnia—Prednisone—prostate cancer	6.63e-05	0.000542	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—prostate cancer	6.58e-05	0.000539	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—prostate cancer	6.54e-05	0.000535	CcSEcCtD
Epinephrine—Vomiting—Etoposide—prostate cancer	6.5e-05	0.000532	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—prostate cancer	6.5e-05	0.000532	CcSEcCtD
Epinephrine—Agitation—Epirubicin—prostate cancer	6.45e-05	0.000528	CcSEcCtD
Epinephrine—Tension—Doxorubicin—prostate cancer	6.38e-05	0.000522	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—prostate cancer	6.31e-05	0.000516	CcSEcCtD
Epinephrine—Palpitations—Epirubicin—prostate cancer	6.21e-05	0.000508	CcSEcCtD
Epinephrine—Nausea—Etoposide—prostate cancer	6.07e-05	0.000497	CcSEcCtD
Epinephrine—Hypertension—Epirubicin—prostate cancer	6.06e-05	0.000496	CcSEcCtD
Epinephrine—Chest pain—Epirubicin—prostate cancer	5.98e-05	0.000489	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—prostate cancer	5.97e-05	0.000489	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.94e-05	0.000486	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—prostate cancer	5.74e-05	0.00047	CcSEcCtD
Epinephrine—Nervous system disorder—Epirubicin—prostate cancer	5.62e-05	0.00046	CcSEcCtD
Epinephrine—Dizziness—Docetaxel—prostate cancer	5.62e-05	0.00046	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—prostate cancer	5.61e-05	0.000459	CcSEcCtD
Epinephrine—Tachycardia—Epirubicin—prostate cancer	5.59e-05	0.000458	CcSEcCtD
Epinephrine—Skin disorder—Epirubicin—prostate cancer	5.57e-05	0.000456	CcSEcCtD
Epinephrine—Hyperhidrosis—Epirubicin—prostate cancer	5.54e-05	0.000453	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—prostate cancer	5.53e-05	0.000453	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.49e-05	0.00045	CcSEcCtD
Epinephrine—Dizziness—Capecitabine—prostate cancer	5.44e-05	0.000445	CcSEcCtD
Epinephrine—Vomiting—Docetaxel—prostate cancer	5.4e-05	0.000442	CcSEcCtD
Epinephrine—Vomiting—Capecitabine—prostate cancer	5.23e-05	0.000428	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—prostate cancer	5.2e-05	0.000426	CcSEcCtD
Epinephrine—Insomnia—Epirubicin—prostate cancer	5.18e-05	0.000424	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—prostate cancer	5.17e-05	0.000424	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—prostate cancer	5.15e-05	0.000422	CcSEcCtD
Epinephrine—Paraesthesia—Epirubicin—prostate cancer	5.15e-05	0.000421	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—prostate cancer	5.13e-05	0.00042	CcSEcCtD
Epinephrine—Somnolence—Epirubicin—prostate cancer	5.09e-05	0.000417	CcSEcCtD
Epinephrine—Nausea—Docetaxel—prostate cancer	5.05e-05	0.000413	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Epirubicin—prostate cancer	4.95e-05	0.000405	CcSEcCtD
Epinephrine—Nausea—Capecitabine—prostate cancer	4.89e-05	0.0004	CcSEcCtD
Epinephrine—Dizziness—Prednisone—prostate cancer	4.85e-05	0.000397	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—prostate cancer	4.8e-05	0.000393	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—prostate cancer	4.76e-05	0.00039	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—prostate cancer	4.71e-05	0.000386	CcSEcCtD
Epinephrine—Vomiting—Prednisone—prostate cancer	4.66e-05	0.000381	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.58e-05	0.000375	CcSEcCtD
Epinephrine—Nausea—Prednisone—prostate cancer	4.35e-05	0.000356	CcSEcCtD
Epinephrine—Dizziness—Epirubicin—prostate cancer	3.79e-05	0.00031	CcSEcCtD
Epinephrine—Vomiting—Epirubicin—prostate cancer	3.64e-05	0.000298	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—prostate cancer	3.51e-05	0.000287	CcSEcCtD
Epinephrine—Nausea—Epirubicin—prostate cancer	3.4e-05	0.000279	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—prostate cancer	3.37e-05	0.000276	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—prostate cancer	3.15e-05	0.000258	CcSEcCtD
Epinephrine—CYP2C9—Metabolism—PPARA—prostate cancer	1.34e-06	9.87e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—TYMS—prostate cancer	1.33e-06	9.84e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SRC—prostate cancer	1.33e-06	9.81e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	1.33e-06	9.8e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NQO1—prostate cancer	1.33e-06	9.8e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.32e-06	9.78e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—prostate cancer	1.32e-06	9.77e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.32e-06	9.76e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—EP300—prostate cancer	1.32e-06	9.75e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTM1—prostate cancer	1.32e-06	9.73e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP9—prostate cancer	1.31e-06	9.69e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	1.31e-06	9.69e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.31e-06	9.68e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	1.31e-06	9.67e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	1.31e-06	9.66e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—TH—prostate cancer	1.31e-06	9.65e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—prostate cancer	1.3e-06	9.64e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.3e-06	9.62e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	1.3e-06	9.61e-06	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	1.3e-06	9.58e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	1.3e-06	9.57e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	1.29e-06	9.55e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—LPL—prostate cancer	1.29e-06	9.55e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	1.29e-06	9.55e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.29e-06	9.53e-06	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.29e-06	9.53e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.29e-06	9.51e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.29e-06	9.5e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	1.29e-06	9.49e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP9—prostate cancer	1.28e-06	9.48e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—prostate cancer	1.28e-06	9.48e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STAT3—prostate cancer	1.28e-06	9.46e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	1.28e-06	9.45e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	1.28e-06	9.43e-06	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.28e-06	9.43e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—prostate cancer	1.28e-06	9.43e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	1.28e-06	9.42e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—AKT1—prostate cancer	1.27e-06	9.4e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.27e-06	9.39e-06	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—AKT1—prostate cancer	1.27e-06	9.36e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	1.27e-06	9.34e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—prostate cancer	1.26e-06	9.33e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	1.26e-06	9.32e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.26e-06	9.31e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CAV1—prostate cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	1.25e-06	9.24e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.25e-06	9.22e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.25e-06	9.21e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—AKT1—prostate cancer	1.25e-06	9.2e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EP300—prostate cancer	1.24e-06	9.19e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	1.24e-06	9.15e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ERCC2—prostate cancer	1.24e-06	9.15e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.24e-06	9.14e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EP300—prostate cancer	1.23e-06	9.11e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GGT1—prostate cancer	1.23e-06	9.1e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.23e-06	9.1e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.23e-06	9.08e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.22e-06	9.02e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.22e-06	9.01e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EP300—prostate cancer	1.22e-06	8.99e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	1.21e-06	8.97e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.21e-06	8.96e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	1.21e-06	8.94e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SRC—prostate cancer	1.21e-06	8.94e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	1.21e-06	8.92e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.2e-06	8.87e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SRC—prostate cancer	1.2e-06	8.86e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.2e-06	8.83e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.2e-06	8.83e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.2e-06	8.83e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.19e-06	8.8e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—prostate cancer	1.19e-06	8.79e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.19e-06	8.78e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	1.19e-06	8.77e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SRC—prostate cancer	1.18e-06	8.74e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—prostate cancer	1.18e-06	8.7e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	1.18e-06	8.7e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.17e-06	8.67e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—prostate cancer	1.17e-06	8.66e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.17e-06	8.65e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	1.17e-06	8.63e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STAT3—prostate cancer	1.17e-06	8.62e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.17e-06	8.62e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—MTHFR—prostate cancer	1.16e-06	8.6e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	1.16e-06	8.6e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.16e-06	8.56e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	1.16e-06	8.54e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—RXRA—prostate cancer	1.15e-06	8.52e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—prostate cancer	1.15e-06	8.52e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EP300—prostate cancer	1.15e-06	8.51e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.15e-06	8.5e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.15e-06	8.47e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.14e-06	8.45e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PPARA—prostate cancer	1.14e-06	8.44e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STAT3—prostate cancer	1.14e-06	8.43e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.14e-06	8.38e-06	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.13e-06	8.38e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.13e-06	8.37e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.12e-06	8.3e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.12e-06	8.29e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SRC—prostate cancer	1.12e-06	8.27e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—EP300—prostate cancer	1.12e-06	8.26e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.12e-06	8.25e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—COMT—prostate cancer	1.11e-06	8.21e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.11e-06	8.17e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.1e-06	8.14e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	1.1e-06	8.12e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.09e-06	8.08e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.09e-06	8.06e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	1.09e-06	8.06e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.09e-06	8.04e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—prostate cancer	1.08e-06	8.01e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—INS—prostate cancer	1.08e-06	8e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.08e-06	8e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TGFB1—prostate cancer	1.08e-06	7.99e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	1.08e-06	7.98e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.07e-06	7.94e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CAV1—prostate cancer	1.07e-06	7.93e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.07e-06	7.93e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.07e-06	7.92e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.07e-06	7.87e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.06e-06	7.85e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.06e-06	7.84e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CREBBP—prostate cancer	1.06e-06	7.84e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—prostate cancer	1.06e-06	7.83e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EGFR—prostate cancer	1.06e-06	7.83e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.06e-06	7.82e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TGFB1—prostate cancer	1.06e-06	7.82e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.06e-06	7.8e-06	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.05e-06	7.78e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.05e-06	7.76e-06	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PIK3CA—prostate cancer	1.05e-06	7.74e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.04e-06	7.71e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.04e-06	7.7e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EGFR—prostate cancer	1.04e-06	7.66e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.04e-06	7.66e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.03e-06	7.61e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—TYMS—prostate cancer	1.03e-06	7.6e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.03e-06	7.58e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PIK3CA—prostate cancer	1.02e-06	7.53e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.02e-06	7.51e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.02e-06	7.51e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	1.01e-06	7.46e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.01e-06	7.44e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.01e-06	7.43e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.01e-06	7.43e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—prostate cancer	1e-06	7.41e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—prostate cancer	1e-06	7.4e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	1e-06	7.39e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—LPL—prostate cancer	9.98e-07	7.37e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	9.93e-07	7.33e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—prostate cancer	9.88e-07	7.3e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	9.87e-07	7.29e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	9.85e-07	7.28e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	9.83e-07	7.26e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	9.82e-07	7.25e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	9.81e-07	7.25e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—prostate cancer	9.8e-07	7.24e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SRC—prostate cancer	9.79e-07	7.23e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CG—prostate cancer	9.78e-07	7.22e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—prostate cancer	9.77e-07	7.22e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PIK3CA—prostate cancer	9.76e-07	7.21e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	9.66e-07	7.14e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.64e-07	7.12e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	9.57e-07	7.07e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ERCC2—prostate cancer	9.56e-07	7.06e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	9.54e-07	7.04e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—NOS3—prostate cancer	9.5e-07	7.02e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	9.44e-07	6.97e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EP300—prostate cancer	9.36e-07	6.91e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	9.27e-07	6.85e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—INS—prostate cancer	9.26e-07	6.84e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	9.21e-07	6.8e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	9.13e-07	6.74e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	9.12e-07	6.74e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SRC—prostate cancer	9.1e-07	6.72e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CREBBP—prostate cancer	9.07e-07	6.7e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	9.01e-07	6.65e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—MTHFR—prostate cancer	8.98e-07	6.64e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—prostate cancer	8.95e-07	6.61e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—prostate cancer	8.91e-07	6.58e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	8.86e-07	6.54e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—prostate cancer	8.82e-07	6.52e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PPARA—prostate cancer	8.81e-07	6.51e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—prostate cancer	8.77e-07	6.48e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	8.77e-07	6.48e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CB—prostate cancer	8.77e-07	6.48e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	8.75e-07	6.46e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—prostate cancer	8.71e-07	6.43e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTGS2—prostate cancer	8.69e-07	6.42e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CD—prostate cancer	8.6e-07	6.35e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	8.58e-07	6.34e-06	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—AKT1—prostate cancer	8.56e-07	6.32e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	8.52e-07	6.29e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	8.39e-07	6.19e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—AKT1—prostate cancer	8.32e-07	6.15e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CAV1—prostate cancer	8.29e-07	6.12e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CA—prostate cancer	8.28e-07	6.11e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	8.25e-07	6.1e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—prostate cancer	8.24e-07	6.09e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—prostate cancer	8.15e-07	6.02e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—prostate cancer	8.15e-07	6.02e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	8.13e-07	6.01e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NOS3—prostate cancer	8.12e-07	6e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—prostate cancer	8.11e-07	5.99e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	8.11e-07	5.99e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—prostate cancer	8.08e-07	5.97e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—AKT1—prostate cancer	7.98e-07	5.89e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—prostate cancer	7.97e-07	5.89e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	7.97e-07	5.89e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—prostate cancer	7.58e-07	5.6e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.55e-07	5.58e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—prostate cancer	7.54e-07	5.57e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	7.53e-07	5.56e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—AKT1—prostate cancer	7.52e-07	5.55e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CB—prostate cancer	7.49e-07	5.54e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	7.45e-07	5.5e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	7.45e-07	5.5e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTGS2—prostate cancer	7.43e-07	5.48e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—prostate cancer	7.43e-07	5.48e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—AKT1—prostate cancer	7.36e-07	5.43e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—EP300—prostate cancer	7.23e-07	5.34e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—prostate cancer	7.21e-07	5.32e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—INS—prostate cancer	7.15e-07	5.28e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CREBBP—prostate cancer	7e-07	5.17e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	6.96e-07	5.14e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	6.92e-07	5.11e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	6.85e-07	5.06e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—AKT1—prostate cancer	6.76e-07	4.99e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—prostate cancer	6.7e-07	4.94e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.64e-07	4.9e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—prostate cancer	6.6e-07	4.87e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—prostate cancer	6.48e-07	4.78e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NOS3—prostate cancer	6.27e-07	4.63e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—EP300—prostate cancer	6.18e-07	4.56e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—prostate cancer	6.13e-07	4.53e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	6.08e-07	4.49e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.78e-07	4.27e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS2—prostate cancer	5.73e-07	4.23e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	5.65e-07	4.18e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.35e-07	3.95e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—prostate cancer	5e-07	3.69e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—EP300—prostate cancer	4.77e-07	3.52e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CA—prostate cancer	4.57e-07	3.37e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—AKT1—prostate cancer	4.37e-07	3.23e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—AKT1—prostate cancer	3.73e-07	2.76e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.53e-07	2.6e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—AKT1—prostate cancer	2.88e-07	2.13e-06	CbGpPWpGaD
